By: IPP Bureau
Last updated : April 01, 2022 10:07 pm
No new studies have been requested
Merck announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date of the supplemental biologics license application (sBLA) for Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) in infants and children to July 1, 2022. The FDA requested additional analyses of data from the pediatric studies, which Merck has submitted to the FDA. No new studies have been requested by the FDA.
In December 2021, Merck announced that the FDA accepted the company’s application for Vaxneuvance for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age and it was granted Priority Review.
“We are confident in the strength of the data from our pediatric studies with Vaxneuvance and will continue to work expeditiously with the FDA to bring this important vaccine forward to infants and children in the United States as soon as possible,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories.